PolyPid Ltd. (NASDAQ: PYPD) stock jumped 10.20% on Tuesday to $1.08 against a previous-day closing price of $0.98. With 15.61 million shares changed hands, the volume of the stock remained heavier than its average volume of 87140.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.2900 whereas the lowest price it dropped to was $0.9576. The 52-week range on PYPD shows that it touched its highest point at $6.90 and its lowest point at $0.65 during that stretch. It currently has a 1-year price target of $3.38.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PYPD was up-trending over the past week, with a rise of 27.06%, but this was up by 52.11% over a month. Three-month performance surged to 8.00% while six-month performance fell -79.27%. The stock lost -77.73% in the past year, while it has gained 54.84% so far this year. A look at the trailing 12-month EPS for PYPD yields -2.43 with Next year EPS estimates of -0.86. For the next quarter, that number is -0.36. This implies an EPS growth rate of -8.00% for this year and 57.00% for next year.
Float and Shares Shorts:
At present, 19.60 million PYPD shares are outstanding with a float of 15.48 million shares on hand for trading. On Oct 13, 2022, short shares totaled 0.51 million, which was 2.59% higher than short shares on Sep 14, 2022. In addition to Ms. Dikla Czaczkes Akselbrad as the firm’s Chief Exec. Officer, Ms. Dalit Hazan serves as its Exec. VP of R&D and Clinical & Regulatory Affairs.
Through their ownership of 15.79% of PYPD’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 1.78% of PYPD, in contrast to 1.18% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in PYPD with 0.49% of the stake, Victory Capital Management, Inc. holds 95,759 shares worth 95,759. A second-largest stockholder of PYPD, Simplex Trading LLC, holds 84,944 shares, controlling over 0.44% of the firm’s shares. Yelin Lapidot Mutual Fund Managem is the third largest shareholder in PYPD, holding 72,572 shares or 0.37% stake. With a 0.45% stake in PYPD, the USAA Small Cap Stock Fund is the largest stakeholder. A total of 88,426 shares are owned by the mutual fund manager. The Yelin Lapidod, which owns about 0.24% of PYPD stock, is the second-largest Mutual Fund holder. It holds 47,015 shares valued at 32769.0. Apo Emerging Health holds 0.17% of the stake in PYPD, owning 33,570 shares worth 23398.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PYPD since 4 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PYPD analysts setting a high price target of $4.00 and a low target of $2.50, the average target price over the next 12 months is $3.38. Based on these targets, PYPD could surge 270.37% to reach the target high and rise by 131.48% to reach the target low. Reaching the average price target will result in a growth of 212.96% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. PYPD will report FY 2022 earnings on 02/07/2024. Analysts have provided yearly estimates in a range of -$1.65 being high and -$3.18 being low. For PYPD, this leads to a yearly average estimate of -$2.24. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. PolyPid Ltd. surprised analysts by $0.06 when it reported -$0.48 EPS against a consensus estimate of -$0.54. The surprise factor in the prior quarter was $0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.35 and the low estimate is -$0.48. The average estimate for the next quarter is thus -$0.41.